Work

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN

Year: 2026
Type: article
Abstract: BACKGROUND: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. METHODS: In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. RESULTS: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. CONCLUSIONS: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7225989856
FWCI:
Cites:
Cited by:
Related to: 10